195 related articles for article (PubMed ID: 37843277)
1. Angiopoietin-2 blockade suppresses growth of liver metastases from pancreatic neuroendocrine tumors by promoting T cell recruitment.
Lee E; O'Keefe S; Leong A; Park HR; Varadarajan J; Chowdhury S; Hiner S; Kim S; Shiva A; Friedman RA; Remotti H; Fojo T; Yang HW; Thurston G; Kim M
J Clin Invest; 2023 Oct; 133(20):. PubMed ID: 37843277
[TBL] [Abstract][Full Text] [Related]
2. RSUME is implicated in tumorigenesis and metastasis of pancreatic neuroendocrine tumors.
Wu Y; Tedesco L; Lucia K; Schlitter AM; Garcia JM; Esposito I; Auernhammer CJ; Theodoropoulou M; Arzt E; Renner U; Stalla GK
Oncotarget; 2016 Sep; 7(36):57878-57893. PubMed ID: 27506944
[TBL] [Abstract][Full Text] [Related]
3. Angiopoietin-2-Dependent Spatial Vascular Destabilization Promotes T-cell Exclusion and Limits Immunotherapy in Melanoma.
Park HR; Shiva A; Cummings P; Kim S; Kim S; Lee E; Leong A; Chowdhury S; Shawber C; Carvajal R; Thurston G; An JY; Lund AW; Yang HW; Kim M
Cancer Res; 2023 Jun; 83(12):1968-1983. PubMed ID: 37093870
[TBL] [Abstract][Full Text] [Related]
4. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
[TBL] [Abstract][Full Text] [Related]
5. A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics.
Sadanandam A; Wullschleger S; Lyssiotis CA; Grötzinger C; Barbi S; Bersani S; Körner J; Wafy I; Mafficini A; Lawlor RT; Simbolo M; Asara JM; Bläker H; Cantley LC; Wiedenmann B; Scarpa A; Hanahan D
Cancer Discov; 2015 Dec; 5(12):1296-313. PubMed ID: 26446169
[TBL] [Abstract][Full Text] [Related]
6. Cross-talk among MEN1, p53 and Notch regulates the proliferation of pancreatic neuroendocrine tumor cells by modulating INSM1 expression and subcellular localization.
Capodanno Y; Chen Y; Schrader J; Tomosugi M; Sumi S; Yokoyama A; Hiraoka N; Ohki R
Neoplasia; 2021 Sep; 23(9):979-992. PubMed ID: 34352404
[TBL] [Abstract][Full Text] [Related]
7. Multiregion WES of metastatic pancreatic neuroendocrine tumors revealed heterogeneity in genomic alterations, immune microenvironment and evolutionary patterns.
Jiang Y; Dong YH; Zhao SW; Liu DY; Zhang JY; Xu XY; Chen H; Chen H; Jin JB
Cell Commun Signal; 2024 Mar; 22(1):164. PubMed ID: 38448900
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic Neuroendocrine Tumors in Mice Deficient in Proglucagon-Derived Peptides.
Takano Y; Kasai K; Takagishi Y; Kikumori T; Imai T; Murata Y; Hayashi Y
PLoS One; 2015; 10(7):e0133812. PubMed ID: 26192435
[TBL] [Abstract][Full Text] [Related]
9. Role of Tumor-Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs).
Cai L; Michelakos T; Deshpande V; Arora KS; Yamada T; Ting DT; Taylor MS; Castillo CF; Warshaw AL; Lillemoe KD; Ferrone S; Ferrone CR
Clin Cancer Res; 2019 Apr; 25(8):2644-2655. PubMed ID: 30670493
[TBL] [Abstract][Full Text] [Related]
10. Compound genetically engineered mouse models of cancer reveal dual targeting of ALK1 and endoglin as a synergistic opportunity to impinge on angiogenic TGF-β signaling.
Eleftheriou NM; Sjölund J; Bocci M; Cortez E; Lee SJ; Cunha SI; Pietras K
Oncotarget; 2016 Dec; 7(51):84314-84325. PubMed ID: 27741515
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for short recurrence-free survival after resection of pancreatic neuroendocrine tumor (PanNET) liver metastases: which patients should undergo resection?
Masui T; Nagai K; Anazawa T; Kasai Y; Sato A; Nakano K; Uchida Y; Yogo A; Kawaguchi Y; Takaori K; Uemoto S
Scand J Gastroenterol; 2020 Apr; 55(4):479-484. PubMed ID: 32223573
[No Abstract] [Full Text] [Related]
12. MEN1 Degradation Induced by Neddylation and the CUL4B-DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression.
Xu J; Ye Z; Zhuo Q; Gao H; Qin Y; Lou X; Zhang W; Wang F; Wang Y; Jing D; Fan G; Zhang Y; Chen X; Chen J; Xu X; Yu X; Ji S
Cancer Res; 2023 Jul; 83(13):2226-2247. PubMed ID: 36939378
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors.
Soler A; Figueiredo AM; Castel P; Martin L; Monelli E; Angulo-Urarte A; Milà-Guasch M; Viñals F; Baselga J; Casanovas O; Graupera M
Clin Cancer Res; 2016 Dec; 22(23):5805-5817. PubMed ID: 27225693
[TBL] [Abstract][Full Text] [Related]
14. MYBL1 induces transcriptional activation of ANGPT2 to promote tumor angiogenesis and confer sorafenib resistance in human hepatocellular carcinoma.
Zhu J; Wu Y; Yu Y; Li Y; Shen J; Zhang R
Cell Death Dis; 2022 Aug; 13(8):727. PubMed ID: 35987690
[TBL] [Abstract][Full Text] [Related]
15. FAM83A promotes the progression and metastasis of human pancreatic neuroendocrine tumors by inducing the epithelial-mesenchymal transition via the PI3K/AKT and ERK pathways.
Zhou B; Zhou X; Zhan C; Jin M; Yan S
J Endocrinol Invest; 2023 Jun; 46(6):1115-1130. PubMed ID: 36344884
[TBL] [Abstract][Full Text] [Related]
16. Tumor Cell-Derived Angiopoietin-2 Promotes Metastasis in Melanoma.
Abdul Pari AA; Singhal M; Hübers C; Mogler C; Schieb B; Gampp A; Gengenbacher N; Reynolds LE; Terhardt D; Géraud C; Utikal J; Thomas M; Goerdt S; Hodivala-Dilke KM; Augustin HG; Felcht M
Cancer Res; 2020 Jun; 80(12):2586-2598. PubMed ID: 32303578
[TBL] [Abstract][Full Text] [Related]
17. Evolutionary Trajectories of Primary and Metastatic Pancreatic Neuroendocrine Tumors Based on Genomic Variations.
Xu M; Yan J; Hu B; Wu C; Gu H; Qi Z; Chen T; Yang W; Zheng Y; Dong H; Sheng W; Long J
Genes (Basel); 2022 Sep; 13(9):. PubMed ID: 36140756
[TBL] [Abstract][Full Text] [Related]
18. Angiopoietin-2 exacerbates cardiac hypoxia and inflammation after myocardial infarction.
Lee SJ; Lee CK; Kang S; Park I; Kim YH; Kim SK; Hong SP; Bae H; He Y; Kubota Y; Koh GY
J Clin Invest; 2018 Nov; 128(11):5018-5033. PubMed ID: 30295643
[TBL] [Abstract][Full Text] [Related]
19. Parallel Signaling through IRE1α and PERK Regulates Pancreatic Neuroendocrine Tumor Growth and Survival.
Moore PC; Qi JY; Thamsen M; Ghosh R; Peng J; Gliedt MJ; Meza-Acevedo R; Warren RE; Hiniker A; Kim GE; Maly DJ; Backes BJ; Papa FR; Oakes SA
Cancer Res; 2019 Dec; 79(24):6190-6203. PubMed ID: 31672843
[TBL] [Abstract][Full Text] [Related]
20. Rb and p53 Execute Distinct Roles in the Development of Pancreatic Neuroendocrine Tumors.
Yamauchi Y; Kodama Y; Shiokawa M; Kakiuchi N; Marui S; Kuwada T; Sogabe Y; Tomono T; Mima A; Morita T; Matsumori T; Ueda T; Tsuda M; Nishikawa Y; Kuriyama K; Sakuma Y; Ota Y; Maruno T; Uza N; Masuda A; Tatsuoka H; Yabe D; Minamiguchi S; Masui T; Inagaki N; Uemoto S; Chiba T; Seno H
Cancer Res; 2020 Sep; 80(17):3620-3630. PubMed ID: 32591410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
